The Kerala Health Minister K. Muraleedharan announced the formation of a special medical board to investigate whether the use of expired Remdesivir contributed to deaths among Nipah patients in Kerala. The move follows concerns raised in the Kerala Assembly on 29 October 2026 about the possible administration of expired medicine.
Key Developments
- The board will be chaired by Aravind R., head of the Infectious Diseases department at Government Medical College Hospital, Thiruvananthapuram.
- Both the Director of Medical Education and the Director of Health Services have been asked to submit a list of all patients who received Remdesivir.
- Investigations will also examine any side‑effects experienced by patients who were administered the drug.
Important Facts
Remdesivir is procured in Kerala only through KMSCL. The last bulk purchase was on 3 June 2021 from the supplier Karunya, costing ₹42 lakh for 3,000 vials, with an expiry date of 30 May 2023. Hospital records show the following usage:
- 2023‑24: 102 vials
- 2024‑25: 34 vials
- 2025‑26: 10 vials
- 2026‑27: 50 vials (imported from Bahrain for a Nipah case)
Given the expiry date, the vials used in 2023, 2024 and 2025 were likely past‑date. The six Nipah cases reported in 2023 resulted in two deaths; both cases in 2024 died; three cases in 2025 saw two deaths; the single case in 2026 recovered.
Exam Relevance
This episode touches upon several UPSC themes:
- Public health governance: Role of state ministries, medical boards, and procurement agencies in ensuring drug safety.
- Drug regulation and supply chain: Importance of expiry monitoring, transparent procurement, and emergency use authorisation.
- Disaster and epidemic management: How Kerala’s health system responds to emerging zoonotic threats like Nipah.
- Accountability mechanisms: Legislative oversight (assembly questions) and executive action (formation of board).
Way Forward
To prevent recurrence, the state should:
- Implement a real‑time inventory tracking system for all high‑risk medicines, flagging expiry dates before distribution.
- Strengthen the procurement protocol of KMSCL with periodic audits and public disclosure of purchase contracts.
- Mandate post‑marketing surveillance for emergency‑use drugs like Remdesivir, documenting adverse events in a central database.
- Ensure that any imported drug, such as the Bahrain shipment, complies with national regulatory standards before clinical use.
- Provide regular training to hospital pharmacists and clinicians on drug safety and expiry management.
These steps will enhance drug safety, protect patients, and reinforce Kerala’s reputation for robust health governance.